Osiris Therapeutics

Osiris Therapeutics is producer of medicines of reparative medicine, founded in 1992. The headquarters of the company is located in the State of Maryland, the USA. Osiris Therapeutics produces a number of the medicines used in the course of recovery of skin, a bone tissue and a cartilage. Also bone and cartilaginous autotransplant who are applied to surgical treatment of local defects of a cartilage of a knee joint are among products. More than 70% of its sales are the share of two products: Grafix (it is used for regeneration of skin at extensive wounds) and Stravix (it is applied to recovery of soft fabrics).

History

2019: Smith & Nephew purchased Osiris Therapeutics for $660 million

On March 12, 2019 the British producer of medical products Smith & Nephew announced acquisition of Osiris Therapeutics for $660 million Smith & Nephew announced that it will pay shareholders of Osiris Therapeutics $19 of own means for each stock owned by them. A day earlier, on March 11, the stocks Osiris were closed on a mark of $18.88. The stocks Osiris rose more than 32% since the beginning of year, and the considerable share of growth is caused by the declaration of the transaction.

According to the representative of Smith & Nephew, the transaction should increase the amount of profit of the company and provide new sources of revenue growth. The fast-growing market of reparative and regenerative medicine is of huge interest to Smith & Nephew company, and purchase of Osiris Therapeutics will allow the company to expand easily a service portfolio and to accelerate rates of development of the relevant divisions.

In March, 2019 Smith & Nephew purchased producer of bone and cartilaginous implants Osiris Therapeutics

The CEO of Smith & Nephew Namal Nawana told about intentions of the company to use similar transactions as a business development method in the field of orthopedic reconstruction, sports medicine and care of wounds. Considering rather small cost of Osiris Therapeutics, Smith & Nephew has an opportunity to conclude some more bargains until the end of the year. It is known that in February, 2019 Smith & Nephew conducted negotiations with NuVasive, producer of the medical tools used in backbone surgery, but results were not disclosed yet.^[1]

Notes